Head-to-head evidence
ACC017 vs VH4524184
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV integrase · full HIV pipeline
ACC017
Developed by Jiangsu Aidea Pharmaceutical Group
NCT06719310 · Phase 1/2 · completed
The first stage of this study randomly assigned patients to ACC017 or placebo under double-blind conditions, a strong design, and its primary endpoints include the proportion of patients reaching an undetectable HIV-1 viral load, a disease-defining measure for HIV therapy. However, results have not yet been posted, so whether the drug met that goal is not yet known.
Next expected readout: June 2027 · NCT07711210 (registry estimate)
VH4524184
Developed by ViiV Healthcare
NCT06214052 · Phase 2 · completed
The study was randomized and double-blind with matching placebo, but it was very small, with 6, 6, and 7 participants receiving VH4524184 doses and only 3 receiving placebo. Its primary endpoint was a surrogate measure of plasma HIV-1 RNA change, and although the reported mean changes favored the medium and high doses, statistical significance was not reported.
Next expected readout: June 2027 · NCT07202546 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ACC017's landscape · VH4524184's landscape